Agreement Furthers BWXT Medical’s Position as a Global Leader in Actinium Supply Collaboration Enables Fusion to Produce High Purity Actinium-225 at its …
Menu
Agreement Furthers BWXT Medical’s Position as a Global Leader in Actinium Supply Collaboration Enables Fusion to Produce High Purity Actinium-225 at its …
(Ottawa, Ontario – February 1, 2023) – Life-saving Molybdenum-99 (Mo-99) isotopes can now be produced at Ontario Power Generation’s (OPG) Darlington Nuclear …
Agreement augments Fusion’s existing isotope supply as pipeline of clinical stage actinium-based radiopharmaceuticals grows Furthers BWXT Medical’s position as a global leader …
(OTTAWA, ON. – December 1, 2022) – BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. has appointed Andrea …
Company Highlights Growing Nuclear Medicine Product Portfolio and Future Opportunities in Therapeutic Radioisotopes (OTTAWA, ON – September 13, 2022) – BWX Technologies, …
(OTTAWA, ON – June 27, 2022) – BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. has executed a …
Community Inquiries:
Phone: 1.833.657.4565
email: [email protected]
Job Seekers:
Please visit www.bwxt.com/careers
for current opportunities.
For urgent media inquiries, please contact:
Monifa Miller
Senior Director, Corporate Affairs
+1 519.242.8071
[email protected]
